Under the renewal agreement, Ipsen will provide funding for research programs carried out at the Salk Institute by researchers on therapeutic concepts for the treatment of pituitary adenomas, cancer and neurodegenerative diseases.
The partnership has delivered scientific advances in the cancer field such as the development of biological models mimicking human cancerous processes as well as identification of specific cells driving tumor growth.
They have also developed stem cells technology for use in the research of neurodegenerative diseases.
Ipsen chairman and CEO Marc Garidel said by capitalizing on partnerships with research organizations, the company will strengthen its links with the medical and scientific community so as to develop therapies tailoring the needs and expectations of patients and physicians.